During the past decade, M3-Emerging Medical Research, LLC conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 3 clinical trials were completed, i.e. on average, 23.1% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 3 clinical trials were completed. i.e. 27.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "M3-Emerging Medical Research, LLC" #1 sponsor was "Eli Lilly and Company" with 2 trials, followed by "Heron Therapeutics" with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "Bio2 Technologies" with 1 trials sponsored and "Flexion Therapeutics, Inc." with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "M3-Emerging Medical Research, LLC" #1 collaborator was "Incyte Corporation" with 2 trials as a collaborator, "Affibody" with 1 trials as a collaborator, "MCRA" with 1 trials as a collaborator, "Medpace, Inc." with 1 trials as a collaborator and "Premier Research Group plc" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "M3-Emerging Medical Research, LLC" are "Ankylosing Spondylitis" (2 trials), "Rheumatoid Arthritis" (2 trials), "Adhesive Capsulitis" (1 trials), "Analgesia" (1 trials) and "Herniated Lumbar Disk" (1 trials). Many other conditions were trialed in "M3-Emerging Medical Research, LLC" in a lesser frequency.

Most popular intervention types in "M3-Emerging Medical Research, LLC" are "Drug" (9 trials), "Device" (4 trials), "Biological" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Baricitinib" (2 trials), "HTX-011" (2 trials), "Placebo" (2 trials), "TNF Inhibitor" (2 trials) and "ABY-035" (1 trials). Other intervention names were less common.

The vast majority of trials in "M3-Emerging Medical Research, LLC" are 13 trials for "All" genders.

Currently, there are NaN active trials in "M3-Emerging Medical Research, LLC". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in M3-Emerging Medical Research, LLC, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in M3-Emerging Medical Research, LLC, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 2 trials that are defined as “Not Applicable".